Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Essa Pharma (EPIX)

Essa Pharma (EPIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 840,108
  • Shares Outstanding, K 33,780
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,450 K
  • 60-Month Beta 1.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.86
Trade EPIX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.21
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.23
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +53.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.30 +7.28%
on 04/19/21
31.99 -21.85%
on 03/30/21
-5.92 (-19.15%)
since 03/19/21
3-Month
16.09 +55.38%
on 01/27/21
32.69 -23.52%
on 02/11/21
+7.66 (+44.18%)
since 01/20/21
52-Week
3.76 +564.89%
on 04/21/20
32.69 -23.52%
on 02/11/21
+20.91 (+511.98%)
since 04/20/20

Most Recent Stories

More News
ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference

, Texas and , /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer,...

EPI.VN : 8.200 (+7.19%)
EPIX : 25.03 (+0.64%)
ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting

, Texas and VANCOUVER, Canada, /PRNewswire/ -- ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment...

EPI.VN : 8.200 (+7.19%)
EPIX : 25.03 (+0.64%)
ESSA Announces Change to its Board of Directors

, Texas and , /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer,...

EPI.VN : 8.200 (+7.19%)
EPIX : 25.03 (+0.64%)
ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing

VANCOUVER, BC and , /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate...

EPI.VN : 8.200 (+7.19%)
EPIX : 25.03 (+0.64%)
LAWSUIT FILED: Ebix, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP

BOSTON, MA / ACCESSWIRE / March 2, 2021 / Block & Leviton LLP (), a national securities litigation firm, announces that a lawsuit for violation of the federal securities laws has been filed against Ebix,...

EPIX : 25.03 (+0.64%)
EBIX : 28.93 (+0.42%)
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

and , /PRNewswire/ -ESSA Pharma Inc. ("" or the "") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is...

EPIX : 25.03 (+0.64%)
EPI.VN : 8.200 (+7.19%)
ESSA Pharma to Present at Upcoming March Investor Conferences

and VANCOUVER, Canada, /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate...

EPI.VN : 8.200 (+7.19%)
EPIX : 25.03 (+0.64%)
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

EPI.VN : 8.200 (+7.19%)
EPIX : 25.03 (+0.64%)
ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock

VANCOUVER, BC and , /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate...

EPI.VN : 8.200 (+7.19%)
EPIX : 25.03 (+0.64%)
ESSA Pharma Announces Pricing of Public Offering of Common Shares

and , /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today...

EPI.VN : 8.200 (+7.19%)
EPIX : 25.03 (+0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 28.63
2nd Resistance Point 27.25
1st Resistance Point 26.06
Last Price 25.03
1st Support Level 23.49
2nd Support Level 22.11
3rd Support Level 20.92

See More

52-Week High 32.69
Last Price 25.03
Fibonacci 61.8% 21.64
Fibonacci 50% 18.22
Fibonacci 38.2% 14.81
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar